Poniard Pharmaceuticals, Inc. (NASDAQ: PARDD) today announced that Poniard and Allozyne, Inc. have mutually agreed to terminate the Agreement and Plan of Merger and Reorganization dated June 22, 2011. The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market, which is a condition to closing of the merger. Poniard's board of directors is actively exploring alternatives for Poniard's business and assets.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

For Further Information: Media: David Pitts Argot Partners (212) 600-1902 Email Contact

Grafico Azioni Poniard Pharmaceuticals, Inc. (MM) (NASDAQ:PARDD)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Poniard Pharmaceuticals, Inc. (MM)
Grafico Azioni Poniard Pharmaceuticals, Inc. (MM) (NASDAQ:PARDD)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Poniard Pharmaceuticals, Inc. (MM)